Spruce Biosciences Inc. (SPRB)
0.12
-0.00 (-2.44%)
At close: Apr 17, 2025, 3:59 PM
0.12
-2.31%
After-hours: Apr 17, 2025, 07:58 PM EDT
-2.44% (1D)
| Bid | 0.11 |
| Market Cap | 5.01M |
| Revenue (ttm) | 7.1M |
| Net Income (ttm) | -39.43M |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.19 |
| Analyst | Hold |
| Ask | 0.14 |
| Volume | 3,950,527 |
| Avg. Volume (20D) | 925,467 |
| Open | 0.13 |
| Previous Close | 0.12 |
| Day's Range | 0.11 - 0.13 |
| 52-Week Range | 0.11 - 0.87 |
| Beta | 2.39 |
About SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adu...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 21
Stock Exchange NASDAQ
Ticker Symbol SPRB
Analyst Forecast
According to 5 analyst ratings, the average rating for SPRB stock is "Hold." The 12-month stock price forecast is $1.75, which is an increase of 1374.30% from the latest price.
Stock ForecastsEarnings Surprise
Spruce Biosciences has released their quartely earnings
on Apr 15, 2025:
Next Earnings Release
Spruce Biosciences Inc. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago
-58.02%
Spruce Biosciences shares are trading lower. The c...
Unlock content with
Pro Subscription
4 months ago
-20.02%
Spruce Biosciences shares are trading lower after Oppenheimer downgraded the stock from Outperform to Perform.
